Jonathon B. Cohen
Expertise in
26
conditions

Dr. Jonathon B. Cohen

Hematology Oncology
Emory Winship Cancer Institute
1365 Clifton Road Northeast, BldgC, 
Atlanta, GA 
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
26
conditions
Emory Winship Cancer Institute
1365 Clifton Road Northeast, BldgC, 
Atlanta, GA 

Overview

Jonathon Cohen is a Hematologist Oncology provider practicing medicine in Atlanta, Georgia.

Dr. Cohen is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Mantle Cell Lymphoma (MCL), Non-Hodgkin Lymphoma, B-Cell Lymphoma, Bone Marrow Transplant, and Vitrectomy.

Dr. Cohen is board certified in American Board Of Internal Medicine, 2014. He is actively involved in clinical research, co-authoring 167 peer reviewed articles and participating in 19 clinical trials. Dr. Cohen is currently accepting new patients.

Graduate Institution

The University Of Florida College Of Medicine

Specialties

Hematology Oncology

Licenses

Internal Medicine in GA

Board Certifications

American Board Of Internal Medicine, 2014

Fellowships

The Ohio State University

Hospital Affiliations

Emory University Hospital Midtown
Emory Johns Creek Hospital
Emory University Hospital
Saint Joseph's Hospital Of Atlanta, Inc

Languages Spoken

English
Mandarin
Spanish

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

Emory Winship Cancer Institute
1365 Clifton Road Northeast, BldgC, Atlanta, GA 30322

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

19 Clinical Trials

Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Biological, Other
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Prednisone, Rituximab, Vincristine Sulfate
Study Phase: Phase 2
A Phase I Study With an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients With Relapsed/Refractory Hodgkin Lymphoma
A Phase I Study With an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients With Relapsed/Refractory Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: August 19, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Brentuximab, Ipilimumab, Nivolumab
Study Phase: Phase 1/Phase 2
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Drug, Other, Procedure
Study Drugs: Carmustine, Cyclophosphamide, Cytarabine, Etoposide, Ibrutinib, Melphalan
Study Phase: Phase 3
A Phase I/II Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma
A Phase I/II Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma
Enrollment Status: Completed
Publish Date: June 25, 2026
Intervention Type: Drug
Study Drugs: Ixazomib, Ibrutinib
Study Phase: Phase 1/Phase 2
A Pilot Study of Atezolizumab (MPDL3280A) Following Adoptive Cell Transfer in Active Hematologic or Solid Tumor Malignancies
A Pilot Study of Atezolizumab (MPDL3280A) Following Adoptive Cell Transfer in Active Hematologic or Solid Tumor Malignancies
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Procedure, Other, Drug
Study Phase: Phase 1
Tisagenlecleucel Versus Standard of Care in Adult Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial (BELINDA)
Tisagenlecleucel Versus Standard of Care in Adult Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial (BELINDA)
Enrollment Status: Completed
Publish Date: June 12, 2026
Intervention Type: Drug
Study Drugs: Tisagenlecleucel, Platinum-based immunochemotherapy, high dose chemotherapy
Study Phase: Phase 3
Managed Access Programs for CTL019, Tisagenlecleucel
Managed Access Programs for CTL019, Tisagenlecleucel
Enrollment Status: Available
Publish Date: April 23, 2026
Intervention Type: Biological
An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined With Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/ Refractory Follicular Lymphoma
An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined With Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/ Refractory Follicular Lymphoma
Enrollment Status: Completed
Publish Date: February 18, 2026
Intervention Type: Drug
Study Drugs: Zanubrutinib, Obinutuzumab
Study Phase: Phase 2
A Randomized Phase II Trial of Myeloablative Versus Non-Myeloablative Consolidation Chemotherapy for Newly Diagnosed Primary CNS B-cell Lymphoma
A Randomized Phase II Trial of Myeloablative Versus Non-Myeloablative Consolidation Chemotherapy for Newly Diagnosed Primary CNS B-cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: January 30, 2026
Intervention Type: Drug, Procedure
Study Drugs: Carmustine, Cytarabine, Etoposide, Thiotepa, Granulocyte Colony-Stimulating Factor
Study Phase: Phase 2
A Phase 1/2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)
A Phase 1/2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)
Enrollment Status: Completed
Publish Date: January 27, 2026
Intervention Type: Drug
Study Drugs: LOXO-305, Rituximab
Study Phase: Phase 1/Phase 2
View 9 Less Clinical Trials

167 Total Publications

An Evaluation of Ibrutinib and Ixazomib in Patients With Relapsed/Refractory Mantle Cell Lymphoma: PrE0404.
An Evaluation of Ibrutinib and Ixazomib in Patients With Relapsed/Refractory Mantle Cell Lymphoma: PrE0404.
Journal: Clinical lymphoma, myeloma & leukemia
Published: March 09, 2026
Similar Doctors
Expertise in
21
conditions
Dr. Kristie A. Blum
Hematology Oncology
Expertise in
21
conditions
Dr. Kristie A. Blum
Hematology Oncology
Referral may be required
Before you request

Emory Winship Cancer Institute

1365 Clifton Road Northeast, BldgC, 
Atlanta, GA 
 (0.1 miles away)
404-778-1900
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Kristie Blum is a Hematologist Oncology provider practicing medicine in Atlanta, Georgia. Dr. Blum is highly rated in 21 conditions, according to our data. Her clinical expertise encompasses Mantle Cell Lymphoma (MCL), Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Blum is board certified in American Board Of Internal Medicine, 2004. Dr. Blum is currently accepting new patients.

Expertise in
26
conditions
Dr. Edmund K. Waller
Hematology Oncology
Expertise in
26
conditions
Dr. Edmund K. Waller
Hematology Oncology
Referral may be required
Before you request

Emory Winship Cancer Institute

1365 Clifton Road Northeast, BldgC, 
Atlanta, GA 
 (0.1 miles away)
404-778-0519
Languages Spoken:
English, Italian, Mandarin, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Edmund Waller is a Hematologist Oncology provider practicing medicine in Atlanta, Georgia. Dr. Waller is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Graft Versus Host Disease (GvHD), Chronic Graft Versus Host Disease (cGvHD), Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), and Bone Marrow Transplant. Dr. Waller is board certified in American Board Of Internal Medicine, 1991. Dr. Waller is currently accepting new patients.

Expertise in
16
conditions
Dr. Sagar Lonial
Hematology Oncology
Expertise in
16
conditions
Dr. Sagar Lonial
Hematology Oncology
Referral may be required
Before you request

Emory Winship Cancer Institute

1365 Clifton Road Northeast, BldgC, 
Atlanta, GA 
 (0.1 miles away)
404-778-0519
Languages Spoken:
English, Mandarin, Spanish
See accepted insurances
Accepting New Patients

Sagar Lonial is a Hematologist Oncology provider practicing medicine in Atlanta, Georgia. Dr. Lonial is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Smoldering Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Aplastic Anemia, and Bone Marrow Transplant. Dr. Lonial is board certified in American Board Of Internal Medicine, 2000. Dr. Lonial is currently accepting new patients.

Frequently Asked Questions about Dr. Jonathon B. Cohen

How do I make an appointment with Dr. Jonathon B. Cohen?

You can book an appointment with Dr. Jonathon B. Cohen by calling their office at 404-778-1900. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jonathon B. Cohen a top-rated expert for Mantle Cell Lymphoma (MCL)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jonathon B. Cohen is classified as an Elite expert for Mantle Cell Lymphoma (MCL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jonathon B. Cohen specialize in?

While Dr. Jonathon B. Cohen is a Hematology Oncology, they have specific expertise in Mantle Cell Lymphoma (MCL), Non-Hodgkin Lymphoma, and B-Cell Lymphoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology Oncology.

Does Dr. Jonathon B. Cohen participate in research or clinical trials?

Yes. Dr. Jonathon B. Cohen has published 167 articles and abstracts on conditions like Mantle Cell Lymphoma (MCL). You can view a list of Dr. Jonathon B. Cohen's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Jonathon B. Cohen accept my insurance?

Dr. Jonathon B. Cohen accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 404-778-1900 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Cohen's expertise for a condition
ConditionClose
View All 7 Elite Conditions
View All 10 Distinguished Conditions
View All 9 Advanced Conditions
View All 39 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile